Paul has 18 years of experience in the healthcare sector on the sell-side and was top-rated by a
number of institutional investment clients. He was one of the first research partners at Redburn,
Europe’s leading independent research firm. His work there included bespoke projects on
healthcare portfolio construction for several institutions. Paul was previously an analyst and
corporate financier at UBS Warburg and studied biochemistry.
Brett Darke (joined 1 September 2017) has 11 years experience covering healthcare and the wider lifesciences sector on the buy-side at TT International, on both long-only and long/short funds. Brett previously worked for five years in corporate finance at Merrill Lynch and Bear Stearns. He holds and Masters degree in Medicine and Management studies from Cambridge University and is a CFA charterholder.
Daniel has over 16 years of experience in the healthcare sector. He joined Bellevue Asset
Management AG in 2004 and was appointed head of portfolio management for the investment
company BB Biotech in 2010. Previously, he was an asset manager for equity4life Asset
Management Ltd and prior to that an equity analyst at UBS Warburg, covering the biotechnology
sector. Daniel has a PhD in Biotechnology from the Swiss Federal Institute of Technology (ETH)